STARING at yet another pregnancy test, Erica Coronado was thrilled but terrified. The 36-year-old had given up hope of a baby after two years of trying and the agony of a stillbirth. So seeing two ...

Lastly, the researchers observed that while patients who discontinued obesity medications lost significantly less weight compared to those who did not, their weight trajectories remained relatively ...

Novo Nordisk has launched a late-stage trial for its obesity drug candidate, CagriSema, aiming to restore market confidence ...

COPENHAGEN (Reuters) -Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug ...

Eli Lilly and Company ( NYSE: LLY) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 8:00 AM ET Lucas E. Montarce - Executive VP & CFO Michael Czapar - Director of Investor ...

UBS is holding firm on its Buy rating and $1,050 price target for Eli Lilly, driven by faith in the upcoming SURPASS-CVOT ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

“With the semaglutide shortage declared over, Hims now has to transition its model to generate growth from other products ...

Economists around the world are expecting muted U.S. economic growth in the coming quarters, and some indicators suggest a mild recession is a possibility. It may become difficult for investors ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...

Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the ...

Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...